

From: [Matthew Traupman](#)
To: [Trials](#)
Cc: [Fishman, Deborah](#); [Caine, David A.](#); [Ho, Alice](#); [Struthers, Abigail](#); [Denuyl, David](#); [Ray Nimrod](#); [Landon Smith](#); [QE - Samsung Bioepis](#)
Subject: IPR2023-00442 - Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
Date: Tuesday, April 23, 2024 4:56:59 PM

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Dear Honorable Board,

On behalf of Petitioner Samsung Bioepis Co., Ltd. ("SB"), we write to follow up on the question posed by Board during last Friday's oral argument in IPR2023-00442. Specifically, SB understands that the Board inquired whether SB would agree to incorporate into the record of this IPR all evidence and argument regarding whether the claimed exclusion criteria should be given patentable weight that were raised by the parties in IPR2022-01225. Counsel for SB has conferred with its client and confirms that SB is agreeable to this proposal. Specifically, SB agrees to incorporate all evidence and argument relating to the issue of whether the claimed exclusion criteria should be given patentable weight that were raised by the parties in IPR2022-01225. SB understands that this agreement obviates the need for additional briefing on the patentable weight issue in IPR2023-00442.

SB is available at the Board's convenience should it have any additional questions.

Respectfully submitted,
Matthew Traupman
Counsel for Petitioner

Matthew Traupman
Partner
Quinn Emanuel Urquhart & Sullivan, LLP

51 Madison Avenue, 22nd Floor
New York, NY 10010
212-849-7322 Direct
212-849-7000 Main Office Number
212-849-7100 FAX
matthewtraupman@quinnemanuel.com
www.quinnemanuel.com

NOTICE: The information contained in this e-mail message is intended only for the personal and confidential use of the recipient(s) named above. This message may be an attorney-client communication and/or work product and as such is privileged and confidential. If the reader of this message is not the intended recipient or agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by e-mail, and delete the original message.